Mizuho raised the firm’s price target on Cigna (CI) to $384 from $360 and keeps an Outperform rating on the shares. The firm surveyed 215 physicians over 13 specialties to gauge hospital inpatient and outpatient trends during Q1. The survey suggests both inpatient and outpatient growth trends, while still elevated, appear to have peaked, the analyst tells investors in a research note. Mizuho views the survey as positive for managed care and clinical labs and neutral for hospitals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna initiated with a Buy at Guggenheim
- Trump Weekly: U.S. announces new tariffs, China responds with their own
- FTC halts lawsuit against PBMs after Trump fires commissioners, WSJ says
- Cigna’s Strategic Shift and Evernorth Focus Drive Positive Outlook Amid Market Challenges
- Health insurers received duplicate payments for Medicaid patients, WSJ reports